Metabolism, excretion, and pharmacokinetics of oral brivanib in patients with advanced or metastatic solid tumors

Drug Metabolism and Disposition

Volumn 38, Issue 11, 2010, Pages 1962-1966

  Mekhail, Tarek ^a,b   Masson, Eric ^c   Fischer, Bruce S ^c   Gong, Jiachang ^c   Iyer, Ramaswamy ^c   Gan, Jinping ^c   Pursley, Janice ^c   Patricia, Daniel ^c   Williams, Daphne ^c   Ganapathi, Ram ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b FLORIDA HOSPITAL CANCER INSTITUTE   (United States)

^c BRISTOL MYERS SQUIBB RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRIVANIB; BRIVANIB ALANINATE; CARBON 14;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; BACKACHE; CACHEXIA; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITIVE DEFECT; CONSTIPATION; DIARRHEA; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPHAGIA; FATIGUE; FEMALE; HUMAN; ISOTOPE LABELING; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; MALE; NAUSEA; OVARY CANCER; PRIORITY JOURNAL; SINGLE DRUG DOSE;

ADMINISTRATION, ORAL; AGED; ANTINEOPLASTIC AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOSE-RESPONSE RELATIONSHIP, DRUG; FECES; FEMALE; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASMS; PYRROLES; TRIAZINES;

EID: 78049386779     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.110.033951     Document Type: Article

References (23)

1. Arora A and Scholar EM (2005) Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther 315:971-979.
2. Beumer JH, Beijnen JH, and Schellens JH (2006) Mass balance studies, with a focus on anticancer drugs. Clin Pharmacokinet 45:33-58.
3. Bhide RS, Cai ZW, Zhang YZ, Qian L, Wei D, Barbosa S, Lombardo LJ, Borzilleri RM, Zheng X, Wu LI, et al. (2006) Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4] triazin-6-yloxy)propan-2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor. J Med Chem 49:2143-2146.
4. Bhide RS, Lombardo LJ, Hunt JT, Cai ZW, Barrish JC, Galbraith S, Jeyaseelan R Sr, Mortillo S, Wautlet BS, Krishnan B, et al. (2010) The antiangiogenic activity in xenograft models of brivanib, a dual inhibitor of vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinases. Mol Cancer Ther 9:369-378.
5. Cai ZW, Zhang Y, Borzilleri RM, Qian L, Barbosa S, Wei D, Zheng X, Wu L, Fan J, Shi Z, et al. (2008) Discovery of brivanib alaninate ((S)-((R)-1-(4-(4- fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy) propan-2-yl)2-aminopropanoate), a novel prodrug of dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinase inhibitor (BMS-540215). J Med Chem 51:1976-1980.
6. Carmeliet P and Jain RK (2000) Angiogenesis in cancer and other diseases. Nature 407:249-257.
7. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, et al. (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125-134.
8. Faivre S, Delbaldo C, Vera K, Robert C, Lozahic S, Lassau N, Bello C, Deprimo S, Brega N, Massimini G, et al. (2006) Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 24:25-35.
9. Hartmann JT, Haap M, Kopp HG, and Lipp HP (2009) Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects. Curr Drug Metab 10:470-481.
10. Hurwitz H, LoRusso P, Shapiro I, Wolanski A, Chemidlin J, Masson E, Syed S, Kollia G, Fischer B, and Conlon K (2008) Phase 1 study of food effects on pharmacokinetics of brivanib alaninate in patients with advanced or metastatic solid tumors, in Proceedings of the 20th EORTC-NCI-AACR Symposium on "Molecular Targets and Cancer Therapeutics"; 2008 October 21-24; Geneva, Switzerland. Abstr 429, European CanCer Organisation, Brussels, Belgium.
11. Huynh H, Ngo VC, Fargnoli J, Ayers M, Soo KC, Koong HN, Thng CH, Ong HS, Chung A, Chow P, et al. (2008) Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma. Clin Cancer Res 14:6146-6153.
12. Je Y, Schutz FA, and Choueiri TK (2009) Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. Lancet Oncol 10:967-974.
13. Kane RC, Farrell AT, Saber H, Tang S, Williams G, Jee JM, Liang C, Booth B, Chidambaram N, Morse D, et al. (2006) Sorafenib for the treatment of advanced renal cell carcinoma. Clin Cancer Res 12:7271-7278.
14. Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, Sherman M, Schwartz M, Lotze M, Talwalkar J, et al. (2008a) Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 100:698-711.
15. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, et al. (2008b) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378-390.
16. Marathe PH, Kamath AV, Zhang Y, D'Arienzo C, Bhide R, and Fargnoli J (2009) Preclinical pharmacokinetics and in vitro metabolism of brivanib (BMS-540215), a potent VEGFR2 inhibitor and its alanine ester prodrug brivanib alaninate. Cancer Chemother Pharmacol 65:55-66.
17. Miller AA, Murry DJ, Owzar K, Hollis DR, Kennedy EB, Abou-Alfa G, Desai A, Hwang J, Villalona-Calero MA, Dees EC, et al. (2009) Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301. J Clin Oncol 27:1800-1805.
18. Morabito A, De Maio E, Di Maio M, Normanno N, and Perrone F (2006) Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions. Oncologist 11:753-764.
19. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, et al. (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115-124.
20. Nyberg P, Xie L, and Kalluri R (2005) Endogenous inhibitors of angiogenesis. Cancer Res 65:3967-3979.
21. Raoul J-L, Finn R, Kang YK, Park JW, Harris R, Coric V, Donica M, and Walters I (2009) An open-label phase II study of first- and second-line treatment with brivanib in patients with hepatocellular carcinoma (HCC) (abstract). J Clin Oncol 27(15s):abstr 4577.
22. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, and Johnson DH (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542-2550. (Pubitemid 44917502)
23. van Erp NP, Gelderblom H, and Guchelaar HJ (2009) Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev 35:692-706.